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ty cancer therapy. The treatment of nonseminomatous
germ cell tumors (NSGCTs), regardless of origin, with
cisplatin-based chemotherapy regimens, and in particu-
lar cisplatin/etoposide-containing regimens, followed
by aggressive surgical resection of residual disease, cur-
rently is one of the most successful paradigms of multi-
modality cancer therapy.2 However, although histologi-
cally and serologically identical to more common
testicular counterparts, PMNGCTs have a distinctly
poorer prognosis. Our institution has previously report-
ed a 57% 5-year survival in a select group of 28 patients
with PMNGCT after successful first-line chemotherapy
and surgery.3 Other series have reported long-term sur-
vivals ranging between 32% and 44%, which are clearly
inferior to the 70% to 80% reported survivals in patients
N onseminomatous germ cell tumors originating inthe mediastinum (PMNGCTs) are rare, accounting
for only 1% to 3.5% of mediastinal tumors.1 They rep-
resent biologically interesting models for multimodali-
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with metastatic NSGCT of testicular origin after multi-
modality therapy.4-6 We retrospectively reviewed our
16-year experience with patients with PMNGCT in an
attempt to analyze variables that may predict long-term
survival after postchemotherapy resection of residual
disease.
Patients and methods
From 1981 to 1998, 92 patients were admitted to Indiana
University Hospital with the diagnosis of PMNGCT. The
patients included 91 male patients and 1 female patient; how-
ever, 12 (13%) of these patients did not undergo post-
chemotherapy resection because of progressive disease.
Seventy-nine of these patients underwent 82 thoracic surgical
procedures and are the basis of this review. All but 1 of the
patients undergoing resection were male. Ages ranged
between 12 and 46 years (mean 27.9 ± 8.3 years). The vast
majority, 96% (71/75), had an elevated serum tumor marker
(STM), either alpha-fetoprotein (AFP, 70/74) or beta human
chorionic gonadotropin (bHCG, 34/71) (Table I). For most
patients, diagnosis is currently confirmed and categorized
pathologically by fine needle aspiration biopsy. However, 11
patients had serologic diagnosis only. Three patients who had
complete resections before admission were not included in
this review. Radiographic evidence of extramediastinal
metastatic disease was present in 25% (n = 20) of patients,
including lung (n = 11), bone (n = 4), cervical lymph nodes
(n = 6), and retroperitoneal lymph nodes (n = 2). 
First-line chemotherapy consisted of regimens containing
cisplatin/etoposide in 94% (n = 74) of this series, with the
other 5 patients receiving regimens containing either cis-
platin/vinblastine sulfate (Velban) (n = 3) or cisplatin/other
drugs (n = 2). Three patients underwent 2 cycles of cis-
platin/etoposide/bleomycin followed by 2 cycles of high-dose
carboplatin-based chemotherapy with autologous stem cell
rescue after randomization to the experimental arm of the cur-
rent phase III intergroup trial for high-risk germ cell cancer as
first-line therapy. First-line chemotherapy was administered
at our institution in 38 patients; the other 41 received first-line
chemotherapy at outside hospitals. Second-line chemothera-
py was given to 8 patients (10%) who demonstrated either
radiographic and/or serologic progressive disease with first-
line therapy. Second-line chemotherapy consisted of high-
dose carboplatin-based chemotherapy with autologous stem
cell rescue in 3 patients, vinblastine sulfate, ifosfamide, and
cisplatin in 1, and etoposide, ifosfamide, and cisplatin in 4. All
patients received second-line chemotherapy at our institution. 
In 51 patients STMs returned to normal limits after first-
line chemotherapy; however, a rising STM was noted in 4 of
these patients and surgery was deferred until completion of
second-line chemotherapy (Table II). STMs subsequently
returned to normal limits in 4 of these patients but not in 2
patients who received high-dose carboplatin-based chemo-
therapy with autologous stem cell rescue. Of the 28 patients
in whom STMs did not return completely to normal limits, 4
received second-line chemotherapy. The STM returned to
normal limits in 1 patient but not in the other 3, 1 of whom
received high-dose carboplatin-based chemotherapy with
autologous stem cell rescue. Fifty patients, therefore, had
normal STMs at operation and 29 had elevated STMs. It is
our current institutional approach to perform resection in
patients with PMNGCT who have elevated STMs after first-
line chemotherapy if anatomically feasible. The results with
second-line chemotherapy in this patient population have
been dismal.7
Hospital records were reviewed and other variables record-
ed, which may be predictive of long-term survival, including
AFP at diagnosis, before, and immediately after the operation
(normal, 21-100, 101-1,000, 101-10,000 and > 10,000
ng/mL), bHCG at diagnosis, before, and immediately after
the operation (normal, 2-100, 101-1,000, 1,001-10,000 and >
10,000 ng/mL), and prechemotherapy pathology (yolk sac,
embryonal, teratoma, choriocarcinoma, and other pathology
[sarcoma, carcinoma, and primitive neuroectodermal carci-
noma], Table I).
Seventy-seven of these patients underwent thoracic surgery
for removal of residual disease at our institution, and 2 under-
went surgery elsewhere after successful first-line chemothera-
py at Indiana University Hospital. Thoracic surgery was typi-
cally delayed for 4 weeks after chemotherapy, which allowed
the patient and, in particular, the bone marrow to recover.
Surgery for PMNGCT is technically demanding because pre-
operative chemotherapy often renders surrounding mediasti-
Table I. Patient characteristics
No. of patients Percent of series
AFP levels (ng/mL)
Normal 4 5
21-100 6 8
101-1,000 8 10
101-10,000 34 43
>10,000 22 28
bHCG levels (ng/mL) 
Normal 39 49
2-100 16 20
101-10,000 11 14
1,001-10,000 3 4
>10,000 2 3
Pathology
Yolk sac 40 51
Embryonal 17 22
Teratoma 23 29
Choriocarcinoma 4 5
Other 7 9
Sarcoma 4
Carcinoma 2
Other 1
Some patients had more than one pathologic diagnosis demonstrated by
prechemotherapy biopsy including all patients with teratomatous elements
(teratoma). AFP, Alpha-fetoprotein; bHCG, beta human chorionic gonado-
tropin; PNET, primitive neuroectodermal tumor.
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nal tissues fibrotic, obscuring normal anatomic planes. Our
surgical technique involving aggressive en bloc removal of the
residual mass after chemotherapy and surrounding adherent
structures has been previously described and was used in the
majority of these cases.3 In summary, the epicenter of the
residual mass is located in the anterior mediastinum and typi-
cally is adherent to adjacent pericardium requiring en bloc
removal. Not infrequently, the residual mass is also adherent
to the mediastinal surfaces of the lung, great veins, phrenic
nerves, and occasionally the cardiac chambers. Over the past
year, we have modified our surgical approach. After exposure
of the residual mass, “4-quadrant” core biopsy specimens are
judiciously obtained with a Core needle (Anchor Products,
Addison, Ill), avoiding tumor “spillage,” and pathologically
analyzed by frozen section. If benign disease (either necrosis
or teratoma) is confirmed, then efforts are made to carefully
separate the phrenic nerve within the periphrenic fat pad from
the residual mass by means of sharp dissection with a No. 15
blade scalpel. Similarly, great venous or large anatomic pul-
monary resections are avoided in these cases, if possible. If a
more conservative resection has been performed, frozen sec-
tion analysis of phrenic nerve, great vein, and/or pulmonary
margins is also obtained before chest closure. In light of
potentiating bleomycin lung toxicity, efforts are made during
and after the operation to minimize fluid administration. The
vast majority of these patients will be operated on after
chemotherapy with baseline sinus tachycardia (heart rate 100-
120 beats/min), which is not treated with fluid and/or phar-
macologic blockade if blood pressure and urine output remain
adequate. 
Operative variables were recorded for each patient, includ-
ing the number of thoracic surgical procedures required to
achieve complete extirpation of residual disease and the tho-
racic surgical approach used for removal of the residual mass
(sternotomy, left or right thoracotomy, and/or bilateral anteri-
or thoracotomies with transsternal extension [clamshell]).
The requirement for en bloc pericardium, pulmonary (wedge,
lobectomy, or total pneumonectomy), phrenic nerve, great
vein, cardiac chamber, and/or diaphragm resection, and finally
the need for separate pulmonary metastasectomy was
obtained from operative records. Surgical disease was record-
ed as 1 of 5 categories (necrosis, teratoma, persistent
NSGCT, sarcomatous degeneration, or carcinomatous degen-
eration). In cases in which mixed surgical disease was pres-
ent, the “worst case” pathologic category was recorded (eg,
necrosis with a focus of persistent NSGCT = persistent
NSGCT). Operative morbidity, mortality, and status at last
follow-up examination (alive, dead, or alive with disease)
were obtained from hospital records or by contacting refer-
ring physicians when necessary. If late death occurred,
whether primarily attributable to local recurrence, distant
recurrence, treatment-related disease (ie, pulmonary fibrosis
caused by bleomycin), or non–treatment-related disease (ie,
acute leukemia), the cause was recorded when information
was available.
With respect to the effect on long-term survival, age at pre-
sentation, the only continuous variable, was analyzed by Cox
regression. Kaplan-Meier analysis was used to calculate sur-
vival and to determine the effect on survival of the following
discrete variables: STM at presentation, preoperatively, and
postoperatively; the presence of extramediastinal disease; the
presence of pulmonary metastases; and preoperative and
postoperative disease. Variables that were found to be predic-
tive of survival with a P value < .10 were entered into a mul-
tivariate analysis using the Cox regression to identify a set of
variables that were independently predictive.
Results
Seventy-nine patients underwent 82 thoracic surgical
procedures (Table III). In 67% the approach was
through a median sternotomy (n = 53), a left thoraco-
tomy approach was used in 17 patients, a clamshell
incision in 7, and a right thoracotomy in the remaining
2 patients. Forty-five patients required en bloc pericar-
Table II. Chemotherapy treatment and STM elevation as compared with pathologic category of residual disease
STM after initial CTx 2nd-line CTx STM after 2nd-line CTx Residual mass pathology
Normal (n = 51) No (n = 47) N/A Necrosis (n = 10)
Teratoma (n = 2)
NSGCT (n = 9)
Carcinoma/sarcoma (n = 7)
Yes (n = 4) Normal (n = 2) Necrosis and teratoma
Elevated (n = 2)* NSGCT (n = 2)
Elevated (n = 28) No (n = 24) N/A Necrosis (n = 7)
Teratoma (n = 6)
NSGCT (n = 10)
Sarcoma (n = 1)
Yes (n = 4) Normal (n = 1) Necrosis (n = 1)
Elevated (n = 3)* Persistent (n = 3)
STM after initial CTx, Serum tumor marker levels after first-line chemotherapy; 2nd-line CTx, if second-line chemotherapy was administered; STM after 2nd-line
CTx, serum tumor marker level after second-line chemotherapy; N/A, STM after second-line chemotherapy was not applicable in patients who did not receive sec-
ond-line chemotherapy; Residual mass pathology, pathologic category of residual mass after the operation; NSGCT, persistent NSGCT. 
*Number of patients treated with high-dose carboplatin-based chemotherapy with autologous stem cell rescue for second-line therapy.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 4
Kesler et al   695
dial resection (57%). Pulmonary resection was required
in 46 (58%) patients, with most (n = 32) undergoing
wedge resection of adjacent lung. En bloc lobectomy
and pneumonectomy were performed in 9 and 5
patients, respectively. One left pneumonectomy was
performed with cardiopulmonary bypass support
because of tumor involvement of the main pulmonary
artery. The ipsilateral phrenic nerve was removed with
the residual mass in 18 patients. Prophylactic diaphrag-
matic plication was typically performed in these
patients unless a substantial amount of lung had been
removed (ie, lobectomy or pneumonectomy). The left
innominate vein was removed in 10 patients and was
not reconstructed unless a patent superior vena cava or
right innominate vein was removed as well (n = 3). In
these patients, orthotopic great venous reconstruction
was accomplished with an externally stented polytetra-
fluoroethylene vascular prosthesis* placed from the
remaining left innominate vein to the superior vena
cava–right atrial junction. Four patients required car-
diac chamber resection. A large area of right atrium
was replaced with a patch of autogenous pericardium
in 1 patient with the aid of cardiopulmonary bypass,
and the atrial involvement was limited to the
appendages, allowing primary closure without bypass,
in 2 other patients. In a final patient, sarcomatous
degeneration involving the lateral wall of the left ven-
tricle required partial-thickness myocardial resection
including a circumflex coronary artery branch without
cardiopulmonary bypass. Seven patients required pul-
monary metastasectomy; 4 of these operations were
performed at the time of extirpation of the residual
mass, and the other 3 were sequentially performed at a
separate thoracotomy (34, 51, and 200 days after the
initial operation). Four patients required staged
extrathoracic surgical procedures, including cerebral
metastasectomy (n = 1), cervical lymphadenectomy (n
= 2), and retroperitoneal lymphadenectomy (n = 1).
Three operative deaths occurred (4%), all attributable
to pulmonary complications. One patient died of adult
respiratory distress syndrome after en bloc right
upper/middle lobe wedge resection and superior vena
cava resection and the other 2 died of bacterial pneu-
Table III. Surgical approach and other organs
removed with the residual mass
No. of patients Percent
Approach to residual mass
Sternotomy 53 67
Left thoracotomy 17 22
Right thoracotomy 2 3
Clamshell 7 9
En bloc resection
Pericardium 45 57
Pulmonary 46
Wedge 32 41
Lobectomy 9 11
LUL 8
RUL, RML 1
Pneumonectomy 5 6
Left 4*
Right 1
Phrenic nerve 18 23
Left 14
Right 4
Great vein 19 24
Left innominate vein 10
SVC/right innominate vein 9
Cardiac chamber 4 5
Right atrium 2*
Left atrium 1
Left ventricle 1
Diaphragm 3 4
Pulmonary metastasectomy 6 8
LUL, Left upper pulmonary lobe; RUL, right upper pulmonary lobe; RML,
right middle pulmonary lobe; SVC, superior vena cava. 
*Cardiopulmonary bypass without cardiac arrest was used (n = 2).
Fig 1. Long-term survival for patients who underwent
postchemotherapy resection of residual disease (Surgery) and
all presenting patients (Series), including patients who were
not operated on, at the Indiana University Medical Center
(1982-1998). Numbers represent patients at risk for death,
which are the same for both curves at each break point.
*Gore-Tex vascular prosthesis, registered trade name of W. L. Gore
& Associates, Inc, Flagstaff, Ariz.
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monias, which occurred in 2 of the 5 patients requiring
pneumonectomy. Operative morbidity occurred in 6 of
the 79 other patients having thoracic surgical proce-
dures: prolonged air leaks (>10 days) necessitating the
patient’s discharge with indwelling chest tubes con-
nected to 1-way valves (n = 3), nonfatal pneumonia (n
= 1), upper gastrointestinal hemorrhage requiring
endoscopic intervention (n = 1), and return to the oper-
ating room for minor bleeding (n = 1). There were 28
late deaths, the majority (86%) of which were due to
recurrent cancer. In 5 of the 18 (28%) patients in whom
information was available, local recurrence at the ini-
tial site in the mediastinum was the cause of death. All
5 of these patients had persistent NSGCT in the resid-
ual mass, equating to a 21% (5/24) incidence of medi-
astinal recurrence with this pathologic category. Three
late deaths were attributed to acute leukemia and 1 to
pulmonary fibrosis. Three patients are currently alive
with disease. Excluding 2 patients lost to long-term fol-
low-up (both of whom had teratoma in the residual
mass), 43 of 77 (56%) patients are alive and free of dis-
ease after an average follow-up interval of 60.8 months
(range 4-175 months) (Fig 1).
Comparing survivors and nonsurvivors, age at pre-
sentation had no predictive value (mean 27.7 years vs
28.2 years, respectively; P = .8). Table IV demonstrates
the influence of discrete variables on survival. AFP
level in excess of 10,000 ng/mL at the time of diagno-
sis had a somewhat poorer prognosis than lower AFP
levels (mean survival 99 vs 103 months, respectively).
Only 2 patients, both of whom were long-term sur-
vivors, had a bHCG level greater than 10,000 ng/mL;
therefore this variable could not be included in the sur-
vival analysis. The presence of extramediastinal dis-
ease at the time of presentation did tend to diminish
mean survival (73 months vs 104 months for patients
without extramediastinal disease); however, this vari-
able was not significantly predictive. There was a sim-
ilar trend toward poorer survival in patients who had
pulmonary metastases as compared with those who did
not, but this variable did not reach statistical signifi-
cance in our series (P = .2). Interestingly, patients who
had pulmonary metastases that were successfully treat-
ed with chemotherapy and did not require subsequent
metastasectomy (n = 4) had a mean survival that was
inferior but statistically equivalent to that of 68 patients
who did not have pulmonary metastases (98 ± 24 vs
105 ± 10 months, respectively). Survival in these 2
Table IV. The influence of analyzable discrete variables
on survival
Mean Alive/total 
Prognostic variable survival (mo) patients (%) P value
AFP before chemotherapy 
(ng/mL)
>10,000 99 ± 12 31/52 (60) 0.39
<10,000 103 ± 14 15/22 (68)
AFP after chemotherapy 
(ng/mL)
Normal 104 ± 11 34/55 (62) <0.01
21-100 44 ± 8 9/17 (53)
101-1,000 — 5/5 (100)
1,000-10,000 9 ± 4 0/2 (0)
STM preop
Normal 105 ± 12 32/50 (64) 0.38
Elevated 85 ± 13 16/29 (55)
Normal postop 117 ± 13 14/18 (78) <0.01
Elevated postop 16 ± 4 1/8 (13)
Extramediastinal disease
Absent 104 ± 12 38/59 (64) 0.49
Present 73 ± 12 10/20 (50)
Lung metastases
Absent 105 ± 10 43/68 (63) 0.23
Present 62 ± 17 5/11 (46)
No surgery 98 ± 24 3/4 (75) <0.01
Surgery 34 ± 11 2/7 (29)
Prechemotherapy teratoma
Present 110 ± 20 14/23 (61) 0.45
Absent 89 ± 9 34/56 (61)
AFP after chemotherapy, Levels after first-line chemotherapy; STM preop,
normal, AFP < 21 ng/mL and bHCG < 2 ng/mL; elevated, AFP > 21 ng/mL
or bHCG > 2 ng/mL; normal and elevated, normal and elevated markers of
those patients in whom either marker was elevated at operation and in whom
postoperative STM data were available; extramediastinal disease, disease in
lung parenchyma separate from primary, cervical, or retroperitoneal lymph
nodes or brain at presentation; lung metastases present, no surgery,
chemotherapy cured pulmonary metastases; P value, lung metastases absent
versus present, but no surgery, versus present with surgery; lung metastasis
present, surgery, pulmonary metastases requiring surgery; prechemotherapy
teratoma, evidence of teratomatous elements in mediastinal mass before
chemotherapy.
Table V. Independent predictors of death by Cox
regression analysis
Hazard ratio 
Prognostic variable (95% CI) P value
Residual mass pathology
Teratoma 5.6 (0.7-44.9) .10
Persistent NSGCT 15.2 (2.0-116.6) .01
Carcinoma 6.6 (0.4-108.6) .18
Sarcoma degeneration 22.2 (2.4-203.6) .01
AFP after chemotherapy
21-100 1.3 (0.5-3.3) .59
101-1,000 <0.1 (no deaths) .98
1,001-10,000 6.5 (1.3-33.2) .03
Residual mass pathology and AFP postchemotherapy hazard ratios calculated
with “tumor necrosis” and “normal” as reference groups, respectively. CI,
Confidence interval; NSGCT, nonseminomatous germ cell tumor; AFP, alpha-
fetoprotein.
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groups was statistically better than survival in the 7
patients who required subsequent pulmonary metasta-
sectomy (P < .01).
Prechemotherapy pathologic tumor type was not sig-
nificantly predictive of survival. Of patients who under-
went prechemotherapy biopsy, only 4 had elements of
choriocarcinoma, which is believed to be a poor prog-
nostic factor, precluding statistical analysis. However, 3
of these patients are alive and well. On the other hand,
patients having teratomatous elements, believed to be a
positive prognostic finding, demonstrated no survival
advantage as compared with patients without teratoma-
tous elements (Table IV). An AFP level greater than
1000 ng/mL after first-line chemotherapy was found to
be negatively predictive of survival, which was signifi-
cant as compared with lower postchemotherapy levels
(P < .01). With respect to STMs in general, 32 of 50
(64%) patients with preoperative normal STMs are sur-
viving as compared with only 16 of 29 (55%) patients
who had elevated STMs at operation. This difference
failed to reach statistical significance in our series (P =
.4). STMs did not return completely to normal limits
before the operation in 26 patients. Postoperatively,
they did return to normal limits in 18 patients, and sur-
vival was significantly better in these 18 than in the 8
in whom STMs did not return to normal (mean survival
117 vs 16 months; P < .01). 
The pathologic finding of complete tumor necrosis in
the residual mass predicted excellent survival (mean
139 ± 8 months). Only 1 late death was attributable to
pulmonary fibrosis among 19 patients, which was sta-
tistically significant as compared with the other patho-
logic categories (P < .01) (Fig 2). The finding of ter-
atoma (n = 28) predicted intermediate survival (mean
111 ± 16 months, P < .01 vs persistent NSGCT and sar-
comatous degeneration). Late deaths occurred in 8
patients having teratoma in the residual mass, 3 from
leukemia and the other 5 from tumor recurrence. One
of the 20 surviving patients with teratoma is currently
alive with disease. Twenty-four patients had patholog-
ic evidence of NSGCT in the residual mass with a
mean survival of 52 ± 12 months. Fifteen deaths
occurred in this group, 3 postoperative and 12 cancer
related. Of the 8 survivors in this group, 7 are free of
disease. Survival was poor in patients having sarcoma-
tous degeneration (n = 5), with no survivors past 57
months. Four of these patients have died of recurrent
disease and the only survivor is not disease free. Three
patients were found to have carcinomatous degenera-
tion in the residual mass, 2 of whom are alive and well.
Low patient numbers in this group precluded statistical
comparison with the other pathology groups, however.
Finally, 3 discrete variables—pathologic category of
the residual mass, AFP level after first-line chemother-
apy, and the presence of pulmonary metastases neces-
sitating surgery—were entered into a multivariate sur-
Fig 2. Long-term survival based on postchemotherapy pathologic category. Numbers represent patients at risk for
death.
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vival analysis. Pathologic category and AFP level were
found to be independent predictors of postoperative
survival (Table V). AFP levels greater than 1000 ng/mL
increased the hazard ratio for death by a factor of 6.5 as
compared with normal AFP levels. Sarcomatous
degeneration and persistent NSGCT in the residual
mass increased the chance of death by factors of 22.2
and 15.2, respectively, as compared with tumor necro-
sis only. The risk of death was increased 5.6-fold in
patients having benign teratoma after chemotherapy,
but this difference did not reach statistical significance
from the tumor necrosis category.
Discussion 
NSGCTs originating in the testes represent a true
success story of multimodality therapy, with a better
death-to-case ratio than cancers of the thyroid or
Hodgkin’s lymphoma. Cisplatin/etoposide-based
chemotherapy regimens with or without surgical extir-
pation of residual disease will result in cure in 70% to
80% of cases. Despite identical histologic features, the
relative inability of standard cisplatin/etoposide/
bleomycin chemotherapy to achieve similar results for
PMNGCT reflects the distinctly different biologic
behavior. Known associations with Klinefelter’s syn-
drome and the propensity for hematologic malignant
diseases to develop, which are usually fatal, further
support the unique biologic nature of PMNGCT.8,9
The interesting biologic nature of PMNGCT, and
NSGCT in general, with respect to potential for conver-
sion to a wide variety of pathologic diagnoses after cis-
platin-based chemotherapy, has been previously
described.10 Although low AFP levels after chemothera-
py were significantly predictive of survival after surgery,
it is perhaps not surprising that the pathologic findings of
either necrosis or benign teratoma in the residual mass
were more predictive. A similar concept is currently rec-
ognized in the treatment of more frequently occurring
thoracic malignant tumors, such as lung and esophageal
cancers, with statistically better survival found in the
subset of patients who have had a complete pathologic
response to neoadjuvant therapy.11,12
New therapeutic strategies are necessary in the treat-
ment of patients with PMNGCT to achieve survivals
equivalent to those of testicular NSGCT. Of the 79
patients who underwent surgery in our series, 41% or
32 patients had persistent cancer in the residual mass
after standard cisplatin-based chemotherapy regimens.
In a preliminary report, Walsh and coworkers13 have
recently reported on 8 of 10 patients surviving 2 years
after a very aggressive 8-drug chemotherapy regimen
followed by surgery. At our institution, we strongly
encourage enrollment in the phase III intergroup trial
for high-risk germ cell cases, which includes
PMNGCT, randomizing patients to receive either 4
cycles of cisplatin/etoposide/bleomycin chemotherapy
(standard arm) or 2 cycles of cisplatin/etoposide/
bleomycin chemotherapy followed by 2 cycles of high-
dose carboplatin/etoposide/cyclophosphamide with
autologous stem cell rescue (experimental arm). The
experimental arm in this phase III study is based on
promising data from Motzer and coworkers,14 report-
ing 22 cases of high-risk germ cell tumor, including 5
patients with PMNGCT who received high-dose carbo-
platin/etoposide chemotherapy with autologous stem
cell rescue as first-line therapy.14
Previously, we3 had emphasized the importance of
normalization of STM before surgical extirpation of
residual disease in patients with PMNGCT, including,
if necessary, the use of second-line chemotherapy in
patients whose markers remained elevated after first-
line therapy. Second-line chemotherapy is anticipated
to cure between 25% and 50% of testicular NSGCTs.
Unfortunately, however, less than 5% of refractory
PMNGCTs are curable with second-line chemotherapy
including patients undergoing autologous stem cell res-
cue and high-dose carboplatin-based chemotherapy.7
These data have changed our treatment algorithm with
respect to patients whose STM levels have not returned
to normal but who otherwise have anatomically opera-
ble residual disease as determined by computed tomo-
graphic imaging after first-line chemotherapy. Of the
24 patients in our series with histologic evidence of
persistent NSGCT in the residual mass, 8 have survived
and 7 of these patient remain free of disease, demon-
strating the ability of surgery to “salvage” select
patients. This is analogous to the ability of retroperi-
toneal lymph node dissection to “salvage” chemore-
fractory NSGCT of testicular origin.15 In addition to
aggressive surgical extirpation of visible disease with
wide surgical margins, patients found to have persistent
NSGCT in the residual mass currently also receive 2
additional cycles of cisplatin/etoposide chemotherapy
if they demonstrated a favorable serologic response to
chemotherapy before the operation. Equally important,
these data demonstrate the less than perfect sensitivity
of elevated STM corresponding to persistent NSGCT
after chemotherapy. Although 29 patients had elevated
markers at operation in our series, only 15 had persis-
tent NSGCT in the residual mass, with 6 patients hav-
ing teratoma and 7 having necrosis only. Further
chemotherapy in these later 13 patients obviously
would have increased morbidity without therapeutic
benefit. There was an equal lack of STM specificity as
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9 of the 50 patients having normal STMs at operation
were found to have persistent NSGCT in the residual
mass. Given the incomplete sensitivity and specificity
of STM levels for persistent NSGCT, in addition to the
limited benefit of second-line chemotherapy in the
treatment of PMNGCT, we currently believe that oper-
able patients should undergo surgical extirpation of
residual disease after first-line chemotherapy, regard-
less of STM status.
Although the success of chemotheraputic regimens in
PMNGCT is important, skilled thoracic surgery after
chemotherapy is an equally important component for
successful multimodality therapy. We have previously
emphasized an aggressive approach to surgical extirpa-
tion of residual disease.3 However, we have recently
taken a more conservative but complete resectional
approach with patients whose STMs are normal (or
near normal) and in whom intraoperative frozen section
analysis has demonstrated benign histologic character-
istics. In these patients, representing nearly two thirds
of our series, efforts are currently being made to spare
phrenic nerves, which are typically adherent to the
residual mass, and avoid large anatomic pulmonary
resections where possible. The majority of these
patients, although young and otherwise healthy, have
received bleomycin-containing chemotherapeutic regi-
mens, which predictably result in varying degrees of
pulmonary fibrosis. The relatively high incidence of
prolonged air leaks in this series also supports the
notion that the remaining lung tissue is relatively non-
compliant and expands poorly to fill space after the
residual mass is removed. Efforts to spare pulmonary
function are underscored by all 3 operative deaths
being directly attributed to pulmonary complications, 2
involving total pneumonectomy. We do believe, howev-
er, that complete removal of any residual mass that con-
tains necrosis is imperative. We have recently treated a
patient who initially underwent subtotal resection of a
residual left hilar mass histologically demonstrating
tumor necrosis only at an outside hospital. A large
recurrent mass containing sarcomatous degeneration
subsequently developed 2 years later, and he underwent
intrapericardial pneumonectomy at our institution. This
patient died of the disease 8 months after this sec-
ondary thoracic surgical procedure. Although a micro-
scopic focus of sarcoma could have been present in the
residual mass left unresected, it is equally possible that
a histologic finding of tumor necrosis does not uni-
formly predict cellular nonviability. The finding of 7
patients in our series who had complete tumor necrosis
histologically but low levels of STM elevation that nor-
malized postoperatively lends further support to incom-
plete correlation of postchemotherapy histologic find-
ings and potential biologic behavior. In conclusion, we
believe that complete extirpation of the residual mass
after chemotherapy is important regardless of histolog-
ic type, with wide surgical margins including great vein
and limited cardiac chamber resection if necessary, and
in particular when persistent NSGCT, carcinomatous
degeneration, or sarcomatous degeneration is present.
The results of multimodality solid tumor therapy,
including therapy for PMNGCT, depend on both suc-
cessful chemotherapy and surgery. In this regard,
PMNGCT, although rare, represents an excellent treat-
ment model for more common thoracic malignant
tumors. New surgical and chemotherapy strategies are
currently being investigated to minimize operative
morbidity and improve long-term survival equivalent to
NSGCT of nonmediastinal origin.
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Discussion
Dr Scott J. Swanson (Boston, Mass). With this paper, once
again the group from Indiana has put together a large amount
of data concerning a relatively uncommon tumor, that of
PMNGCT. They are to be congratulated for pursuing an in-
tensive multimodal approach that includes aggressive
surgery, and their perioperative mortality of less than 5% and
low morbidity are outstanding. 
Their paper presents several interesting issues, from which
I have 4 questions. Their prior report in 1990 demonstrated
that the STMs AFP and bHCG have inadequate sensitivity
and specificity. With this larger series of 79 patients, they
now report that even in the face of elevated markers patients
should be operated on after first-line chemotherapy, as 13 out
of 29 patients with elevated markers had favorable histology
at resection. Also they showed that those patients with com-
plete necrosis in the residual mass after chemotherapy had
the best survival, a mean survival of 139 months. In addition,
they showed that those patients with pulmonary metastases
that completely responded to chemotherapy and did not
require resection did as well as those patients who did not
have pulmonary metastases. 
Over the past year, as he mentioned, Dr Kesler and his
colleagues have adopted an approach of 4-quadrant biopsy
during resections. If on rapid sectioning a favorable histo-
logic tumor type is noted, they will limit their surgical
resection by saving the phrenic nerve and limiting the pul-
monary and great vessel resections. In addition, they
observed that patients who had extramediastinal disease did
not fare less well statistically than those with disease limited
to the mediastinum. 
With these issues in mind, my questions for Dr Kesler are
as follows: First, clearly the biology of this tumor is different
from the standard thoracic carcinoma that we see commonly.
Is radical resection really necessary as advocated by your
group for those tumors showing complete necrosis? In those
cases, what is the contribution of surgery? Have you specifi-
cally noted any different outcome in the group over the past
year where a lesser resection is carried out? 
Second, are other biomarkers available that may be more
sensitive and specific than AFP and bHCG? In cases in which
AFP remains greater than 1000 ng/mL before surgery, are
there any other novel therapies to be considered before resec-
tion, for example, antiangiogenic therapy? 
Third, is there a role for other functional tests, such as
positron emission tomographic (PET) scanning, to determine
the timing and need for surgery? 
Finally, given that 20% of these tumors with persistent
NSGCT histology showed local recurrence, is there a role for
adjuvant therapy, such as high-dose radiation in the form of
seeds or newer agents such as photodynamic therapy? 
Dr Kesler. Thank you for your kind comments and insight-
ful questions. 
First, we currently believe that if either tumor necrosis or
benign teratoma is demonstrated on intraoperative core
biopsy, then phrenic nerves and/or great veins that are
attached to but not grossly involved by the residual mass may
be spared. We would also make efforts to avoid pneumonec-
tomy if reasonable in these cases. We still emphasize that all
visible evidence of residual disease must be removed despite
“benign” pathology on frozen section. In this respect, aggres-
sive surgery is still mandatory. To date we have not been
“burned” by false negative intraoperative pathologic analysis
or local recurrence using this approach; however, further
study is needed.
Second, we are not aware of any other STMs that have
more sensitivity or specificity for this disease. Patients with
AFP levels greater than 1000 ng/mL at operation certainly
represent a desperate situation. The results of second-line
chemotherapy, however, are very poor in NSGCTs originat-
ing in the mediastinum; therefore, the oncologists at our insti-
tution would still recommend surgery if anatomically feasible
in these patients.
PET scanning has been studied for the evaluation of germ
cell tumors in general and found to be only moderately sen-
sitive. Moreover, we are not at all convinced that tumors
demonstrating complete tumor necrosis histologically, and
therefore PET scan “negative,” would have long-term biolog-
ic inactivity. We therefore believe that complete extirpation of
residual disease would be necessary regardless of PET scan
findings. In summary, PET scanning to determine preopera-
tive planning has not been helpful.
Finally, patients who have persistent germ cell cancer in the
resected residual mass are currently treated with 2 cycles of
platinum-based chemotherapy after the operation only if they
responded to platinum-based chemotherapy before the oper-
ation. If they did not respond preoperatively, we unfortunate-
ly believe that no further standard chemotherapy would be of
value, although investigational drug regimens may be
offered.
Dr David J. Sugarbaker (Boston, Mass). I wonder, Dr
Kesler, whether you could resolve for me one conflict that I
have regarding your presentation. You mentioned your proce-
dure of 4 core biopsies to determine whether you are dealing
with teratoma or a more malignant residual variant after
chemotherapy. At the Dana-Farber Cancer Institute, we have
found that these tumors are often variegated, with areas of
teratomatous change as well as areas of more malignant
residual disease. I wonder whether that procedure will not
lead you to a suboptimal resection in patients with residual
malignant disease. Could you comment on that? 
Dr Kesler. Dr Sugarbaker, we certainly do have concerns
about using a more conservative resectional approach, and we
agree that residual masses after chemotherapy may not
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demonstrate homogeneous histologic features. However, two
thirds of these patients will ultimately be shown to have some
form of benign histology only throughout the residual mass.
Moreover, for patients demonstrating viable germ cell cancer
in the completely resected specimens, we have observed that
the malignant histology is not infrequently harbored closer to
the mass epicenter as opposed to the margins. In either of
these scenarios, we currently believe that removal of adjacent
phrenic nerves and/or great veins will only increase postoper-
ative morbidity without improving cure rates. Certainly,
regardless of a benign intraoperative biopsy report, if a resid-
ual mass cannot be rather readily dissected from great vein
adventitia or periphrenic fat, then a more radical mediastinal
dissection is performed without hesitation. Finally, thus far
our pathologists have been extremely accurate at analyzing
intraoperative core biopsy specimens. In summary, we cur-
rently believe that an aggressive but “balanced” surgical
approach is justified in these cases, although, again, more
studies and follow-up are needed.
Dr Valerie W. Rusch (New York, NY). I want to emphasize
a couple of your comments and also ask you a question. At
Memorial Sloan-Kettering Cancer Center we would endorse
your policy of offering salvage resection to patients who have
completely resectable disease but still have elevated markers,
particularly an elevated AFP level. In addition, our prelimi-
nary experience with PET scanning indicates that this does
not accurately restage the disease after chemotherapy. 
How do you handle the patient who has negative 4-quad-
rant biopsy specimens intraoperatively but elevated STMs
preoperatively?
Dr Kesler. Dr Rusch, as up to 50% of the patients in this
series admitted for surgery with elevated STMs had complete
tumor necrosis or benign teratoma, the finding of viable germ
cell cancer is not a foregone conclusion. Most of these
patients had only modest elevation of STMs (<100 ng/mL),
however. Patients harboring only small foci of active germ
cell cancer within the residual mass likewise usually had only
minor marker elevation before the operation. In either of
these cases, a conservative but complete resection after biop-
sy should not compromise cure. Certainly, however, if a
patient comes to surgery with significant STM elevation and
a poor radiographic response to chemotherapy, we would
directly proceed with wide mediastinal resection without core
biopsy, assuming a large volume of viable germ cell cancer is
remaining. 
Dr Mark J. Krasna (Baltimore, Md). Since you have such
a vast experience, I think we all have taken an aggressive
approach, thanks to the Indiana group’s leadership. 
One question that seems to beckon is a converse of Dr
Sugarbaker’s question: Why not perform biopsies on every-
body, and why not do it before you open the chest? If there is
any residual disease, why not give more chemotherapy at that
time? Clearly you have shown that the best predictor for ulti-
mate survival is the complete response. You are telling us that
there is no second-line chemotherapy. Give more of the same
and then do your 4-quadrant biopsy after you have had a sec-
ond or a third course of the several cycles of chemotherapy.
Dr Kesler. Dr Krasna, our oncologists have demonstrated
that the results of currently available second-line chemothera-
py for this disease are abysmal, effective in less than 7% of
patients after standard first-line platinum/etoposide regimens
fail. In our series, we were able to surgically cure or “salvage”
nearly 30% of our patients with persistent germ cell cancer
found histologically within the resected specimen. For this rea-
son, we do not believe that a second biopsy after first-line
chemotherapy is indicated if resection is anatomically feasible.
Dr L. Penfield Faber (Chicago, Ill). One comment struck
me as being controversial—the fact that you make the diag-
nosis initially on a needle biopsy specimen. It has been my
understanding that a large piece of tissue is needed to confirm
the exact histologic characteristics of these tumors. In other
words, a seminomatous tumor may have mixed histologic
features and, therefore, your treatment program could be
incorrect if you are doing only a needle biopsy. You may
diagnose a seminoma when the tumor is really a mixed tumor
with yolk sac and seminomatous elements. I always do an
anterior mediastinotomy and biopsy a block of tissue for
accurate histologic determination. Would you comment on
the accuracy of needle biopsy in determining histologic type? 
Dr Kesler. Dr Faber, our cytologists are proficient at differ-
entiating nonseminomatous from seminomatous tumors on
fine needle aspiration biopsy alone. We also believe it would
not be totally unreasonable to empirically treat a young man
who has an anterior mediastinal mass and markedly elevated
STMs with standard chemotherapy for PMNGCT without
biopsy. We certainly agree with your point that differentiating
nonseminomatous from seminomatous germ cell tumors, or
other primary mediastinal tumors for that matter, remains crit-
ical in some patients. In these cases, core biopsy performed
percutaneously under computed tomographic guidance or an
open Chamberlain approach would be justified if fine needle
aspiration biopsy was inconclusive or unavailable.
